PTGX - Protagonist Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

673.4M

Cash

313.4M

Avg Qtr Burn

-29.36M

Short % of Float

6.40%

Insider Ownership

1.66%

Institutional Own.

96.22%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rusfertide (PTG-300) (Hepcidin Mimetic) Details Blood cancer, Polycythemia vera	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JNJ-2113 (PN-235) (Oral IL-23 receptor antagonist) Details Psoriasis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JNJ-2113 (PN-235) (Oral IL-23 receptor antagonist) Details Ulcerative colitis	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rusfertide (PTG-300) (Hepcidin Mimetic) Details Genetic disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PTG-200 (IL-23R Antagonist) Details Crohns disease, Inflammatory bowel disease, Inflammatory disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PN-943 (α4β7-Integrin Antagonist) Details Inflammatory bowel disease, Inflammatory disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.